EC Number   |
Application |
Reference |
|---|
   3.4.22.38 | diagnostics |
to assess better the biology of CatK activity in vivo, a novel near-infrared fluorescence (NIRF) probe for imaging of CatK is developed |
679251 |
| 3.4.22.38 | drug development |
Cat K inhibitors might be useful for the treatment of osteoporosis |
696697 |
| 3.4.22.38 | drug development |
Cat S is an attractive therapeutic target and selective Cat S inhibitors may also modulate a number of other diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, asthma, atherosclerosis and neuropathic pain |
696638 |
| 3.4.22.38 | drug development |
cathepsin K inhibitors are regarded as a potential therapy for the treatment of bone loss, such as osteoporosis |
696617 |
| 3.4.22.38 | drug development |
cathepsin K is seen as an attractive target for intervention in the treatment of both osteoporosis and osteoarthritis |
696664 |
| 3.4.22.38 | drug development |
development of cathepsin K inhibitors as an approach for bone diseases with enhanced bone resorption |
699441 |
| 3.4.22.38 | drug development |
lysosomal cysteine protease is an interesting target molecule with therapeutic potential to attenuate bleomycin-induced pulmonary fibrosis in mice |
-, 701180 |
| 3.4.22.38 | drug development |
the enzyme is a drug target in the treatment of osteoporosis |
697257 |
| 3.4.22.38 | medicine |
activation of cathepsin K may be a promising strategy to prevent homing of therapy-resistant glioma stem-like cells (GSLCs) in niches and thus render these cells sensitive to chemotherapy and radiation |
752841 |
| 3.4.22.38 | medicine |
because excessive bone remodeling is a key element in the pathogenesis of postmenopausal osteoporosis and other skeletal disorders, cathepsin K is a potential target for therapeutic intervention |
708689 |
